•
BC
BCRX
BioCryst Pharmaceuticals Inc
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
1.42B
Volume
1.01M
52W High
$11.31
52W Low
$6.00
Open
$6.69
Prev Close
$6.72
Day Range
6.64 - 6.86
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Latest News
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights
GlobeNewswire Inc.•Nov 22
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
GlobeNewswire Inc.•Oct 23
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Benzinga•Oct 14
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Oct 3
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
GlobeNewswire Inc.•Oct 1
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Sep 3
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
Benzinga•Aug 21
BioCryst to Present at Upcoming Investor Conference
GlobeNewswire Inc.•Aug 21